Robert J Hopkin1, Gustavo Cabrera2, Joel Charrow3, Roberta Lemay4, Ana Maria Martins5, Michael Mauer6, Alberto Ortiz7, Manesh R Patel8, Katherine Sims9, Stephen Waldek10, David G Warnock11, William R Wilcox12. 1. Cincinnati Children's Hospital Medical Center, Cincinnati, USA; Department of Pediatrics, University of Cincinnati College Medicine, Cincinnati, USA. Electronic address: rob.hopkin@cchmc.org. 2. Centro Cardiovascular Bolivar, Buenos Aires, Argentina. Electronic address: gustavo.h.cabrera@hotmail.com. 3. Division of Genetics, Birth Defects and Metabolism, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, USA. Electronic address: jcharrow@northwestern.edu. 4. Strategic Epidemiology & Biostatistics, Rare Diseases, Sanofi Genzyme, Cambridge, USA. Electronic address: Roberta.Lemay@genzyme.com. 5. Reference Center for Inborn Errors of Metabolism, Federal University of São Paulo, São Paulo, Brazil. Electronic address: martins.anamaria@uol.com.br. 6. Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, USA. Electronic address: mauer002@umn.edu. 7. Unidad de Dialisis, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, IRSIN, REDINREN, Madrid, Spain. Electronic address: AOrtiz@fjd.es. 8. Division of Cardiovascular Medicine, Duke University School of Medicine, Durham, USA. Electronic address: patel017@mc.duke.edu. 9. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. Electronic address: Sims@Helix.MGH.Harvard.edu. 10. University of Sunderland, Sunderland, United Kingdom. Electronic address: stephen.waldek@sunderland.ac.uk. 11. Division of Nephrology, University of Alabama at Birmingham, Birmingham, USA. Electronic address: dwarnock@uab.edu. 12. Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, USA. Electronic address: william.wilcox@emory.edu.
Abstract
BACKGROUND: Fabry disease, an X-linked lysosomal storage disorder, causes intracellular accumulation of glycosphingolipids leading to progressive renal, cardiovascular, and cerebrovascular disease, and premature death. METHODS: This longitudinal Fabry Registry study analyzed data from patients with Fabry disease to determine the incidence and type of severe clinical events following initiation of enzyme replacement therapy (ERT) with agalsidase beta, as well as risk factors associated with occurrence of these events. Severe events assessed included chronic dialysis, renal transplantation, cardiac events, stroke, and death. RESULTS: The analyses included 969 male and 442 female Fabry patients. The mean age at first agalsidase beta infusion was 35 and 44, and median treatment follow-up 4.3years and 3.2years, respectively. Among males, cardiac events were the most common on-ERT events, followed by renal, stroke, and non-cardiac death. Among females, cardiac events were also most common followed by stroke and renal events. Patients with on-ERT events had significantly more advanced cardiac and renal disease at baseline as compared with patients without on-ERT events. Severe events were also associated with older age at ERT initiation (males and females), a history of pre-ERT events (females; approaching statistical significance in males), and a higher urinary protein/creatinine ratio (females). Approximately 65% of patients with pre-ERT events did not experience subsequent on-ERT events. Of patients without pre-ERT events, most (84% of males, 92% of females) remained event-free. CONCLUSIONS: Patients with on-ERT severe events had more advanced Fabry organ involvement at baseline than those without such events and patients who initiated ERT at a younger age had less residual risk of on-ERT events. The observed patterns of residual risk may aid clinicians in multidisciplinary monitoring of male and female patients with Fabry disease receivingERT, and in determining the need for administration of adjunctive therapies.
RCT Entities:
BACKGROUND:Fabry disease, an X-linked lysosomal storage disorder, causes intracellular accumulation of glycosphingolipids leading to progressive renal, cardiovascular, and cerebrovascular disease, and premature death. METHODS: This longitudinal Fabry Registry study analyzed data from patients with Fabry disease to determine the incidence and type of severe clinical events following initiation of enzyme replacement therapy (ERT) with agalsidase beta, as well as risk factors associated with occurrence of these events. Severe events assessed included chronic dialysis, renal transplantation, cardiac events, stroke, and death. RESULTS: The analyses included 969 male and 442 female Fabry patients. The mean age at first agalsidase beta infusion was 35 and 44, and median treatment follow-up 4.3years and 3.2years, respectively. Among males, cardiac events were the most common on-ERT events, followed by renal, stroke, and non-cardiac death. Among females, cardiac events were also most common followed by stroke and renal events. Patients with on-ERT events had significantly more advanced cardiac and renal disease at baseline as compared with patients without on-ERT events. Severe events were also associated with older age at ERT initiation (males and females), a history of pre-ERT events (females; approaching statistical significance in males), and a higher urinary protein/creatinine ratio (females). Approximately 65% of patients with pre-ERT events did not experience subsequent on-ERT events. Of patients without pre-ERT events, most (84% of males, 92% of females) remained event-free. CONCLUSIONS:Patients with on-ERT severe events had more advanced Fabry organ involvement at baseline than those without such events and patients who initiated ERT at a younger age had less residual risk of on-ERT events. The observed patterns of residual risk may aid clinicians in multidisciplinary monitoring of male and female patients with Fabry disease receiving ERT, and in determining the need for administration of adjunctive therapies.
Authors: Michael Beck; Uma Ramaswami; Elizabeth Hernberg-Ståhl; Derralynn A Hughes; Christoph Kampmann; Atul B Mehta; Kathleen Nicholls; Dau-Ming Niu; Guillem Pintos-Morell; Ricardo Reisin; Michael L West; Jörn Schenk; Christina Anagnostopoulou; Jaco Botha; Roberto Giugliani Journal: Orphanet J Rare Dis Date: 2022-06-20 Impact factor: 4.303
Authors: William R Wilcox; Ulla Feldt-Rasmussen; Ana Maria Martins; Alberto Ortiz; Roberta M Lemay; Ana Jovanovic; Dominique P Germain; Carmen Varas; Katherine Nicholls; Frank Weidemann; Robert J Hopkin Journal: JIMD Rep Date: 2017-05-17
Authors: Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada Journal: Mol Genet Metab Rep Date: 2019-02-06
Authors: Derralynn A Hughes; Patricio Aguiar; Patrick B Deegan; Fatih Ezgu; Andrea Frustaci; Olivier Lidove; Aleš Linhart; Jean-Claude Lubanda; James C Moon; Kathleen Nicholls; Dau-Ming Niu; Albina Nowak; Uma Ramaswami; Ricardo Reisin; Paula Rozenfeld; Raphael Schiffmann; Einar Svarstad; Mark Thomas; Roser Torra; Bojan Vujkovac; David G Warnock; Michael L West; Jack Johnson; Mark J Rolfe; Sandro Feriozzi Journal: BMJ Open Date: 2020-10-10 Impact factor: 2.692
Authors: Andrea Frustaci; Behzad Najafian; Giuseppe Donato; Romina Verardo; Cristina Chimenti; Luigi Sansone; Manuel Belli; Enza Vernucci; Matteo Antonio Russo Journal: J Clin Med Date: 2022-02-28 Impact factor: 4.241
Authors: Letizia Spinelli; Giuseppe Giugliano; Antonio Pisani; Massimo Imbriaco; Eleonora Riccio; Camilla Russo; Alberto Cuocolo; Bruno Trimarco; Giovanni Esposito Journal: Int J Cardiovasc Imaging Date: 2020-11-19 Impact factor: 2.357